Guangzhou LBP Medicine Science & Technology Co Ltd
688393
Company Profile
Business description
Guangzhou LBP Medicine Science & Technology Co Ltd is engaged in production and sales of in vitro diagnostic reagents and instruments. The company's products include Fluorescence in situ hybridization (FISH) series; Immunohistochemistry (IHC) series; Liquid - based cytology (LBP) series; PCR series; and medical laboratory.
Contact
Building 7, No. 11, Nanxiang 3rd Road
Guangzhou High-tech Industrial Development Zone
Guangdong Province
Guangzhou510663
CHNT: +86 2032299997
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
796
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,263.87 | 355.13 | 4.49% |
| DAX 40 | 24,080.63 | 1,159.04 | 5.06% |
| Dow JONES (US) | 47,909.92 | 1,325.46 | 2.85% |
| FTSE 100 | 10,608.88 | 260.09 | 2.51% |
| HKSE | 25,893.02 | 776.49 | 3.09% |
| NASDAQ | 22,634.99 | 617.14 | 2.80% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,782.81 | 165.96 | 2.51% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |